Parkinson's disease is a neurodegenerative brain disorder that causes tremors, rigidity, slowed movements and trouble with balance. While levodopa-based therapies are the most commonly-prescribed treatments for Parkinson’s, their effectiveness decreases over time, resulting in various side effects, particularly Levodopa-induced dyskinesia. The once beneficial doses of the drug designed to replace dopamine loss can leave patients unable to perform daily routine tasks. Amarantus Bioscience Holdings, Inc. (AMBS) ,a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases, is one step closer to providing a solution for those suffering from Levodopa-induced dyskinesia.
Amarantus Bioscience has submitted a request to the US FDA for orphan drug designation (ODD) for eltoprazine in the treatment of levodopa-induced dyskinesia (PD-LID). The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose or prevent orphan diseases and disorders that affect fewer than 200,000 people in the US.
“A successful application to the US FDA for ODD for eltoprazine in PD LID would complete the transition of our therapeutics portfolio into the orphan drug arena, thereby squarely positioning Amarantus as an orphan drug company,” said Gerald E. Commissiong, President and CEO of Amarantus.
Working to Improve Quality of Life
Eltoprazine is a small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression.To date, Eltoprazine has been evaluated in over 680 human subjects, and has a well-established safety profile.
There are an estimated one million people living with Parkinson's disease in the United States. While there is no cure for Parkinson’s, various medications and therapies are utilized to treat the symptoms. Amarantus’ latest development furthers their reputation as a premiere representative of the biotechnology community that strives to develop treatments that improve the quality of life for Parkinson’s patients.
For more information about Amarantus Bioscience, visit www.amarantus.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer